You should know this tiny Canadian biotech stock, analyst says

Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$0.70 target price on Theralase (Theralase Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:TLT) in a Jan. 12 update following the company’s announcement of a new clinical collaboration with Ferring Pharmaceuticals.

Theralase said it has entered into a collaborative clinical development agreement with Ferring to evaluate a combination therapy for Bacillus Calmette–Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. Under the agreement, a new patient cohort will be added to Theralase’s ongoing Phase 2 Ruvidar study to assess Ruvidar in combination with Ferring’s Adstiladrin, the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration for this indication.

The new cohort is expected to enroll approximately 20 patients, initially in the United States, with potential expansion into Canada and other geographies. Enrollment is anticipated to be completed in 2026. While the companies did not disclose who will fund the additional cohort, Uddin said he assumes Theralase will bear the cost and modestly increased his 2026 and 2027 R&D expense estimates to reflect the incremental spend.

Uddin emphasized that the collaboration is not a licensing agreement, but said positive data from the combination cohort could act as a catalyst for a potential licensing transaction over time, either with Ferring or another partner. He added that such a deal would be particularly meaningful given Theralase’s balance sheet and need for non-dilutive capital.

Adstiladrin received FDA approval in 2022 based on a Phase 3 study enrolling 157 patients, with five-year follow-up data published in The Journal of Urology in 2024. At 12 months, the therapy demonstrated a complete response rate of 51%, with a median duration of response of 9.7 months. The safety profile was favourable, with most adverse events reported as Grade 1–2 and no Grade 4 or 5 events observed.

According to Evaluate, Adstiladrin is projected to generate approximately US$98-million in revenue in 2026, rising to US$173-million by 2032.

Uddin said the therapeutic rationale for combining the two agents rests on Adstiladrin’s ability to reprogram bladder cells to produce interferon alpha-2b, enhancing immune recognition of tumour cells, while Ruvidar is designed to selectively destroy cancer cells. In his view, the combination could improve durability of response by pairing direct tumour cell destruction with sustained immune-mediated clearance.

Theralase has now treated 88 of the planned 90 patients in its ongoing Phase 2 Ruvidar study, with the remaining two patients expected to be treated by the first quarter of 2026. Follow-up is anticipated to be completed by the second quarter of 2027.

Despite the scientific progress, Uddin reiterated that Theralase’s balance sheet remains a key risk factor. He said a licensing transaction would represent an attractive source of non-dilutive funding.

-30-